Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 06, 2021; 96 (14) Disputes & Debates: Editors' Choice

Editors' Note: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study

View ORCID ProfileAravind Ganesh, Steven Galetta
First published April 5, 2021, DOI: https://doi.org/10.1212/WNL.0000000000011709
Steven Galetta
Roles: Section Editor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aravind Ganesh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Aravind Ganesh
Steven Galetta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Editors' Note: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study
Aravind Ganesh, Steven Galetta
Neurology Apr 2021, 96 (14) 682; DOI: 10.1212/WNL.0000000000011709

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1

Share

  • Article
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Dr. Lipton et al. examined the prevalence and associated risk factors of opioid use among respondents in the Chronic Migraine Epidemiology and Outcomes study, a cross-sectional, longitudinal web-based study. Of the 2,388 respondents who were using acute prescription medications for migraine, more than one-third used or kept opioids on hand, contrary to guidance. Male sex, high body mass index, allodynia, increasing monthly headache frequency, Total Pain Index score, anxiety, depression, cardiovascular comorbidities, and emergency or urgent care use for headache in the previous 6 months were associated with opioid use. In response, Dr. Gupta cites his experiences in headache care in India and the United Arab Emirates and suggests intravenous metoclopramide as an alternative to opioid use in patients with severe migraine headaches, noting that it can provide analgesia through arginine-vasopressin and opioid release. Noting the different potential psychological effects of mu and delta opioid receptors and arguing that consensus statements and guidelines are insufficient to overcome the opioid abuse crisis, Dr. Gupta emphasizes the importance of understanding migraine pathophysiology and studying nonopioid medications such as metoclopramide. In another response, Dr. Blumenfeld notes that although this study demonstrates that patients using opioids are worse off in many domains, the causal directions cannot be determined. Dr. Blumenfeld posits that worsening headache likely came first, leading to initial opioid use and wonders whether a lack of education about alternative treatment options, as well as misdiagnosis and poor prescribing of migraine-specific medications, may be the real issue here. In a third response, Dr. Minen compares the study with previous work showing that patients presenting to a headache center reported emergency department providers as being the first to prescribe their opioids, and she advocates for better training for emergency and urgent care physicians in headache management. Dr. Minen also notes the need for more headache-specific training for pain specialists because opioid users are more likely to have their headaches managed by such specialists (versus neurologists or headache specialists) and cites ongoing efforts by the American Academy of Pain Medicine and the Pain Medicine journal that are addressing this issue. Dr. Minen also argues that neurologists or headache specialists may be best suited for managing patients with migraine and cardiovascular comorbidities, being more familiar with nonopioid options. Responding to these comments, the authors agree that opioid treatment of migraine may be particularly problematic in the United States and that intravenous metoclopramide is an important nonopioid option for emergency migraine care. They note that nonsteroidal anti-inflammatory drugs, triptans, gepants, ditans, and neuromodulation are also important acute treatment options. They acknowledge that they cannot determine the causal sequence linking opioid use to migraine features and comorbidities but note that in animal models, prolonged opioid exposure can produce latent sensitization and long-lasting changes to descending pain modulation, suggesting mechanistic links for how opioid use may worsen headaches. They suggest that longitudinal studies with close follow-up and daily diaries may help resolve the causal sequence. The authors suggest that gepants, on the other hand, may not exacerbate headache because they do not produce latent sensitization and that such acute agents may be helpful in longitudinal studies. Finally, they agree that additional training and education in headache management is important for emergency and urgent care physicians and pain specialists. This exchange highlights 3 important aspects of tackling opioid use among patients with migraine—the challenges of disentangling various elements in the causal chain; the importance of high-quality, accessible headache-specific education; and the promising role of the growing armamentarium of migraine-specific acute therapies in mitigating opioid use.

Dr. Lipton et al. examined the prevalence and associated risk factors of opioid use among respondents in the Chronic Migraine Epidemiology and Outcomes study, a cross-sectional, longitudinal web-based study. Of the 2,388 respondents who were using acute prescription medications for migraine, more than one-third used or kept opioids on hand, contrary to guidance. Male sex, high body mass index, allodynia, increasing monthly headache frequency, Total Pain Index score, anxiety, depression, cardiovascular comorbidities, and emergency or urgent care use for headache in the previous 6 months were associated with opioid use. In response, Dr. Gupta cites his experiences in headache care in India and the United Arab Emirates and suggests intravenous metoclopramide as an alternative to opioid use in patients with severe migraine headaches, noting that it can provide analgesia through arginine-vasopressin and opioid release. Noting the different potential psychological effects of mu and delta opioid receptors and arguing that consensus statements and guidelines are insufficient to overcome the opioid abuse crisis, Dr. Gupta emphasizes the importance of understanding migraine pathophysiology and studying nonopioid medications such as metoclopramide. In another response, Dr. Blumenfeld notes that although this study demonstrates that patients using opioids are worse off in many domains, the causal directions cannot be determined. Dr. Blumenfeld posits that worsening headache likely came first, leading to initial opioid use and wonders whether a lack of education about alternative treatment options, as well as misdiagnosis and poor prescribing of migraine-specific medications, may be the real issue here. In a third response, Dr. Minen compares the study with previous work showing that patients presenting to a headache center reported emergency department providers as being the first to prescribe their opioids, and she advocates for better training for emergency and urgent care physicians in headache management. Dr. Minen also notes the need for more headache-specific training for pain specialists because opioid users are more likely to have their headaches managed by such specialists (versus neurologists or headache specialists) and cites ongoing efforts by the American Academy of Pain Medicine and the Pain Medicine journal that are addressing this issue. Dr. Minen also argues that neurologists or headache specialists may be best suited for managing patients with migraine and cardiovascular comorbidities, being more familiar with nonopioid options. Responding to these comments, the authors agree that opioid treatment of migraine may be particularly problematic in the United States and that intravenous metoclopramide is an important nonopioid option for emergency migraine care. They note that nonsteroidal anti-inflammatory drugs, triptans, gepants, ditans, and neuromodulation are also important acute treatment options. They acknowledge that they cannot determine the causal sequence linking opioid use to migraine features and comorbidities but note that in animal models, prolonged opioid exposure can produce latent sensitization and long-lasting changes to descending pain modulation, suggesting mechanistic links for how opioid use may worsen headaches. They suggest that longitudinal studies with close follow-up and daily diaries may help resolve the causal sequence. The authors suggest that gepants, on the other hand, may not exacerbate headache because they do not produce latent sensitization and that such acute agents may be helpful in longitudinal studies. Finally, they agree that additional training and education in headache management is important for emergency and urgent care physicians and pain specialists. This exchange highlights 3 important aspects of tackling opioid use among patients with migraine—the challenges of disentangling various elements in the causal chain; the importance of high-quality, accessible headache-specific education; and the promising role of the growing armamentarium of migraine-specific acute therapies in mitigating opioid use.

Footnotes

  • Author disclosures are available upon request (journal{at}neurology.org).

  • See letter

  • See response

  • See letter

  • See response

  • See letter

  • See response

  • © 2021 American Academy of Neurology
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Footnotes
  • Info & Disclosures
Advertisement

Related Articles

  • Reader Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study
  • Author Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study
  • Reader Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study
  • Author Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study
  • Reader Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study
  • Author Response: Characterizing Opioid Use in a US Population With Migraine: Results From the CaMEO Study

Alert Me

  • Alert me when eletters are published
Neurology: 96 (15)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise